The Prognostic Value of Different Molecular Subtypes of Breast Cancer in Relation to Enhancer-of-Zeste Homologue 2 Expression

Journal Title: Journal of Clinical and Diagnostic Research - Year 2019, Vol 13, Issue 7

Abstract

ABSTRACT Introduction: The role of Enhancer-of-zeste homologue 2 (EZH2) in breast cancer invasion and progression may be attributed to EZH2-mediated epigenetic repression of tumour cells. Aim: The study aimed to assess the prognostic value of different luminal subtypes of breast cancer in association with EZH2 protein expression. Materials and Methods: A cross-sectional analytical research study on breast cancer women was performed. The four major molecular subtypes of breast cancer were defined, as follows: luminal A, luminal B, HER2-type, and Triple-Negative/Basal-like (TNBC). Log Rank (Mantel-Cox) test of equality of survival function was then performed to assess statistical significance between groups. The effects of variables on Overall Survival (OS) and Event Free Survival (EFS), was then assessed to give adjusted Hazard Ratios (HRs) with 95% Confidence intervals (CIs). Results: Samples were collected for women with breast cancers, with follow-up data collected over a 5-year period, with the age range of 34-75 years. TNBC subgroup was twice as likely to have high EZH2 expression compared with the luminal A subgroup (as the reference group) (OR=2.06; 95% CI=0.22 to19.09), and the luminal B subgroup had a 35% reduced likelihood (OR=0.66; 95% CI=0.26 to1.70). Cox’s Regression analysis showed that the hazard of mortality was about 3 times more in HER2 subtype breast cancers than in the luminal A subgroup (HR=3.16; 95% CI: 1.30-15.45, p<0.005), while the Log Rank (Mantel-Cox) test showed a statistically significant difference in OS by molecular subtype at all-time points (p≤0.05). Conclusion: The results provide some interesting insights, confirming the prognostic differences by molecular subtypes, in relation to EZH2 protein expression. However, there remains controversy about the prognostic value of different molecular subtypes.

Authors and Affiliations

Zohreh Sanaat, Ashraf Fakhrjou, Faris Farassati, Roya Dolatkhah

Keywords

Related Articles

Acute Native Valve Endocarditis by Granulicatella adiacens

ABSTRACT Infective Endocarditis (IE) is an uncommon but a life-threatening infectious disease. Approximately 3% to 5% of cases of streptococcal infective endocarditis is caused by Nutritionally Variant Streptococci (NVS...

Evaluation of Indications of Saline Infusion Sonohysterography in a Private Hospital in Nigeria: A Retrospective Study

ABSTRACT Introduction: Despite the obvious advantages of Saline Infusion Sonohysterography (SIS) in the evaluation of infertile couples, its uptake is still poor in developing countries. Aim: To evaluate the indications...

Socio-demographic and Lifestyle Determinants of Insomnia among Adult Patients Attending Primary Healthcare Centres, Jeddah: A Cross-sectional Study

ABSTRACT Introduction: Insomnia is the most prevalent sleep disorder. Its prevalence differs worldwide, from 5% to 40% depending on the criteria used to define insomnia, techniques, and method of collecting data. In Saud...

Effect of Cleistanthin A on Voltage Gated Proton Channels of Human Neutrophils

ABSTRACT Introduction: Cleistanthus collinus (C. collinus), a well known plant toxin, contains active principles like Cleistanthin A, Cleistanthin B, Cleistanthin C and Diphyllin. Previous human case reports and animal s...

Download PDF file
  • EP ID EP606684
  • DOI 10.7860/JCDR/2019/41610.13020
  • Views 96
  • Downloads 0

How To Cite

Zohreh Sanaat, Ashraf Fakhrjou, Faris Farassati, Roya Dolatkhah (2019). The Prognostic Value of Different Molecular Subtypes of Breast Cancer in Relation to Enhancer-of-Zeste Homologue 2 Expression. Journal of Clinical and Diagnostic Research, 13(7), 1-6. https://europub.co.uk./articles/-A-606684